KALA BIO settles $10.6M Oxford debt for $2M; issues 4.6M shares to settle claims

KALA BIO, Inc.

Paid $2M to Oxford Finance, settling ~$10.6M debt obligations in full; debt overhang removed.
Issued 900,000 shares to Baker Bros. to resolve participation rights claims under prior financing.
Issued 2,200,000 shares to LifeSci Capital for unpaid financial advisory services.
Issued 1,100,000 shares to Delaware IR to settle $600,000 consulting fee; make-whole provision.
Total 4,600,000 shares issued in private, unregistered transactions (incl. 400,000 to employees).

item 1.01 item 3.02 item 7.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001829126-26-000055
form_type: 8-K
ticker: KALA
cik: 0001479419
company_name: KALA BIO, Inc.
filed_at: 2026-01-06T23:59:59+00:00
discovered_at: 2026-05-14T18:02:35.169038+00:00
generated_at: 2026-05-16T11:31:43.339107+00:00
sec_items: ["1.01", "3.02", "7.01", "9.01"]
event_type: other_material
sentiment: positive
materiality_score: 0.7
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001829126-26-000055
json_url: https://secwatch.observer/filing/0001829126-26-000055.json
markdown_url: https://secwatch.observer/filing/0001829126-26-000055.md
text_url: https://secwatch.observer/filing/0001829126-26-000055.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1479419/000182912626000055/0001829126-26-000055-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1479419/000182912626000055/kalabio_8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001829126-26-000055

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.